| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.26 | 2e-12 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.27 | 3e-12 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.35 | 5e-10 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.37 | 1e-09 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.42 | 2e-09 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.37 | 3e-09 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.39 | 4e-09 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-08 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.24 | 3e-08 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.19 | 5e-08 |